Assembly Biosciences, Inc. (ASMB), a biotechnology company, Thursday announced encouraging interim data from Phase 1b study of ABI-4334 in participants with chronic hepatitis B virus infection.
Results from the first cohort of the Phase 1b study showed strong antiviral activity in participants who were treated with 150 mg dose of ABI-4334, a next-generation capsid assembly modulator (CAM). Further, the drug candidate was well tolerated with a favorable safety profile.
Enrollment is underway for the second and final cohort, evaluating 400 mg dose of ABI-4334 with data expected in the first half of 2025.
Under the collaboration agreement between Assembly Bio and Gilead Sciences, Inc., Gilead has the right to opt in to further development and commercialization for ABI-4334 after Assembly Bio's delivery of a data package following completion of this Phase 1b study, the company noted.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.